Committed to Care, Dedicated to Health
News
Change - Announcement Of Appointment Of Non-Independent And Non-Executive Director
BackJan 02, 2024
| Announcement Title | Change - Announcement of Appointment |
| Date & Time of Broadcast | Jan 2, 2024 17:42 |
| Status | New |
| Announcement Sub Title | APPOINTMENT OF NON-INDEPENDENT AND NON-EXECUTIVE DIRECTOR |
| Announcement Reference | SG240102OTHR9T9J |
| Submitted By (Co./ Ind. Name) | Mr Yet Kum Meng |
| Designation | Chief Executive Officer and Executive Director |
| Description (Please provide a detailed description of the event in the box below) | Appointment of Mr. Abram Melkyzedeck Suhardiman as a Non-Independent and Non-Executive Director. This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "Exchange") and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Ms. Foo Jien Jieng, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg. |
| Additional Details | |
| Date Of Appointment | 02/01/2024 |
| Name Of Person | Abram Melkyzedeck Suhardiman |
| Age | 34 |
| Country Of Principal Residence | Singapore |
| The Board's comments on this appointment (including rationale, selection criteria, board diversity considerations, and the search and nomination process) | The Nominating and Remuneration Committee of the Company has reviewed the qualifications and experience of Mr. Abram Melkyzedeck Suhardiman ("Mr. Abram") and has recommended to the Board of Directors his appointment as a Non-Independent and Non-Executive Director of the Company. The Board of Directors, having reviewed and considered Mr. Abram's qualifications and experience and all information available to-date, is of the view that he is suitable for the appointment as a Non-Independent and Non-Executive Director of the Company and has approved his appointment. |
| Whether appointment is executive, and if so, the area of responsibility | Non-Executive |
| Job Title (e.g. Lead ID, AC Chairman, AC Member etc.) | Non-Independent and Non-Executive Director |
| Professional qualifications | Master's Program in Finance, Hult International Business School, San Francisco, CA, USA Bachelor of Science in Business Administration, University of Southern California |
| Any relationship (including immediate family relationships) with any existing director, existing executive officer, the issuer and/ or substantial shareholder of the listed issuer or any of its principal subsidiaries | Yes. Brother-in-law of Mr Brian Riady, a Non-Independent and Non-Executive Director of the Company Son-in-law of Dr Stephen Riady, who holds controlling deemed interest in the Company |
| Conflict of interests (including any competing business) | Mr Abram holds 68,918,900 shares (representing 1.52% interest) in Healthway Medical Corporation Limited ("HMC") which is in the business of Singapore healthcare services. Mr Abram is also a director of HMC. As at the date of this announcement, the Company, through a wholly-owned subsidiary, holds 1,189,993,563 shares (representing 26.24% interest) in HMC. |
| Working experience and occupation(s) during the past 10 years | March 2023 - Current Executive Vice Chairman, HMC February 2020 - March 2023 Deputy Chief Executive Officer, HMC August 2017 - February 2020 Chief Operating Officer, HMC August 2015 - August 2017 Vice President, Nuvest Capital,Singapore August 2013 - August 2015 Analyst, The Abraaj Group, Singapore |
| Undertaking submitted to the listed issuer in the form of Appendix 7.7 (Listing Rule 704(7)) Or Appendix 7H (Catalist Rule 704(6)) | Yes |
| Shareholding interest in the listed issuer and its subsidiaries? | No |
| # These fields are not applicable for announcements of appointments pursuant to Listing Rule 704 (9) or Catalist Rule 704 (8). | |
| Past (for the last 5 years) | 1. Amazing Early Intervention Pte Ltd (Director) 2. Nuvest Real Return Fund (Non-Executive and Non-Independent Director) |
| Present | 1. Three Eagles Capital Partners Pte Ltd (Director) 2. IPP Financial Advisers Pte Ltd (Director) 3. Union Smile Pte Ltd (Director) 4. Healthway Investment SEA Pte Ltd (Director) 5. Lily Aw Medical Services Pte Ltd (Director) 6. Urohealth Pte Ltd (Director) 7. HSC Health Pte Ltd (Director) 8. Amazing Speech Therapy Director Pte Ltd (Director) 9. Acension Therapy Grp Pte Ltd (Director) 10. Headstart For Life Pte Ltd (Director) 11. Ten Surgery Group Pte Ltd (Director) 12. Telehope Speech Therapy Pte Ltd (Director) 13. IPP Financial Services Holdings Ltd (Director) 14. Straits Podiatry Pte Ltd (Director) 15. The Clinic @ HF Pte Ltd (Director) 16. The Clinic @ Marina One Pte Ltd (Director) 17. The Clinic @ Business City Pte Ltd (Director) 18. The Clinic @ Tai Seng Pte Ltd (Director) 19. The Clinic @ Aperia Pte Ltd (Director) 20. The Clinic @ Capitagreen Ltd (Director) 21. The Clinic @ One George Street Pte Ltd (Director) 22. The Clinic @ Campus Pte Ltd (Director) 23. The Clinic @ Fusionopolis Pte Ltd (Director) 24. EBH Capital Pte Ltd (Director) 25. Moolahgo Pte Ltd (Non-Executive Director) 26. TIH Limited (Alternate Director) 27. Healthway Medical Corporation Limited (Executive Vice Chairman) 28. City Ocean Group Limited (Director) |
| (a) Whether at any time during the last 10 years, an application or a petition under any bankruptcy law of any jurisdiction was filed against him or against a partnership of which he was a partner at the time when he was a partner or at any time within 2 years from the date he ceased to be a partner? | No |
| (b) Whether at any time during the last 10 years, an application or a petition under any law of any jurisdiction was filed against an entity (not being a partnership) of which he was a director or an equivalent person or a key executive, at the time when he was a director or an equivalent person or a key executive of that entity or at any time within 2 years from the date he ceased to be a director or an equivalent person or a key executive of that entity, for the winding up or dissolution of that entity or, where that entity is the trustee of a business trust, that business trust, on the ground of insolvency? | No |
| (c) Whether there is any unsatisfied judgment against him? | No |
| (d) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving fraud or dishonesty which is punishable with imprisonment, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such purpose? | No |
| (e) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such breach? | No |
| (f) Whether at any time during the last 10 years, judgment has been entered against him in any civil proceedings in Singapore or elsewhere involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or a finding of fraud, misrepresentation or dishonesty on his part, or he has been the subject of any civil proceedings (including any pending civil proceedings of which he is aware) involving an allegation of fraud, misrepresentation or dishonesty on his part? | No |
| (g) Whether he has ever been convicted in Singapore or elsewhere of any offence in connection with the formation or management of any entity or business trust? | No |
| (h) Whether he has ever been disqualified from acting as a director or an equivalent person of any entity (including the trustee of a business trust), or from taking part directly or indirectly in the management of any entity or business trust? | No |
| (i) Whether he has ever been the subject of any order, judgment or ruling of any court, tribunal or governmental body, permanently or temporarily enjoining him from engaging in any type of business practice or activity? | No |
| (j) Whether he has ever, to his knowledge, been concerned with the management or conduct, in Singapore or elsewhere, of the affairs of :- | |
| (i) any corporation which has been investigated for a breach of any law or regulatory requirement governing corporations in Singapore or elsewhere; or | No |
| (ii) any entity (not being a corporation) which has been investigated for a breach of any law or regulatory requirement governing such entities in Singapore or elsewhere; or | No |
| (iii) any business trust which has been investigated for a breach of any law or regulatory requirement governing business trusts in Singapore or elsewhere; or | No |
| (iv) any entity or business trust which has been investigated for a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, in connection with any matter occurring or arising during that period when he was so concerned with the entity or business trust? | Yes |
| If Yes, Please provide full details | Yes, please refer to Annex A for details. |
| (k) Whether he has been the subject of any current or past investigation or disciplinary proceedings, or has been reprimanded or issued any warning, by the Monetary Authority of Singapore or any other regulatory authority, exchange, professional body or government agency, whether in Singapore or elsewhere? | No |
| Any prior experience as a director of an issuer listed on the Exchange? | Yes |
| If Yes, Please provide details of prior experience | Mr Abram was appointed as an Executive Director of HMC, a company listed on the Catalist Board of the SGX-ST until 8 November 2023, in 2019. He was re-designated as HMC's Deputy Chief Executive Officer in 2020 and re-designated as HMC's Executive Vice Chairman in 2023. He is also an Alternate Director on the Board of TIH Limited since 2020, a company listed on the Main Board of SGX-ST. |
| Please provide details of relevant experience and the nominating committee's reasons for not requiring the director to undergo training as prescribed by the Exchange (if applicable) | Not Applicable. |
Attachments
- Annex A (Size: 195,894 bytes)